Amedisys (AMED)
(Delayed Data from NSDQ)
$96.13 USD
+1.70 (1.80%)
Updated May 20, 2024 04:00 PM ET
After-Market: $96.14 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.13 USD
+1.70 (1.80%)
Updated May 20, 2024 04:00 PM ET
After-Market: $96.14 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
Zacks News
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.
Amedisys (AMED) Beats Q2 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 3.05% and -0.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
3 Reasons to Add LHC Group (LHCG) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of deals and a broad array of services.
Amedisys (AMED) Latest New York Assets Buyout Aids Home Health
by Zacks Equity Research
The latest development remains in line with Amedisys' (AMED) ongoing efforts to expand footprint in key markets.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice
by Zacks Equity Research
Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.
Encompass Health (EHC) to Expand Inpatient Rehabilitation Unit
by Zacks Equity Research
Encompass Health (EHC) to construct an inpatient rehabilitation hospital to capture a market with great prospects.
Amedisys (AMED) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Amedisys' (AMED) Contessa Buyout to Boost Home Health Business
by Zacks Equity Research
Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.
DVA or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. AMED: Which Stock Is the Better Value Option?
5 Reasons That Make Encompass Health (EHC) an Attractive Bet
by Zacks Equity Research
Encompass Health's (EHC) optimistic business prospects make it a lucrative stock to own for strong gains.
Encompass Health (EHC) Expands Inpatient Rehab Business
by Zacks Equity Research
Encompass Health (EHC) continues to strengthen its inpatient rehabilitation business by opening a hospital.
Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT
by Zacks Equity Research
Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.
Here's Why You Should Retain LHC Group (LHCG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of buyouts and a broad array of services.
Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
by Zacks Equity Research
Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.
Why You Should Add Veeva Systems (VEEV) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Syneos' (SYNH) New Patient Consortium to Drive Innovation
by Zacks Equity Research
Syneos' (SYNH) Patient Voice Consortium incorporates patient perspective across wide range of communities to guide product development lifecycle.
DVA vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. AMED: Which Stock Is the Better Value Option?
Here's Why You Should Retain PRA Health (PRAH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.
Cooper Companies (COO) Unit's Ortho-K Lens Receives CE Mark
by Zacks Equity Research
Cooper Companies' (COO) unit CooperVision's latest orthokeratology contact lens becomes the latest myopia control product to gain European approval.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.
BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch
by Zacks Equity Research
BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.